UnicoCell Biomed Co (TPE:6794) Current Deferred Revenue: NT$0.00 Mil (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

TPE:6794 UnicoCell Biomed Co Ltd TPE:6794
80 GF Score
Price NT$71.80
GF Value NT$64.97
Valuation Modestly Overvalued
! 2 Warning Signs
View Full Analysis

What is UnicoCell Biomed Co Current Deferred Revenue?

UnicoCell Biomed Co TPE:6794 +1.41% 80 Current Deferred Revenue is NT$0.00 Mil as of Jun. 2026. GuruFocus rates TPE:6794 with a GF Score™ of 80/100 and a GF Value™ of NT$64.97 (Modestly Overvalued). The stock has 2 warning signs investors should review.

Current Deferred Revenue represents collections of cash or other assets related to revenue producing activity for which revenue has not yet been recognized. Generally, an entity records deferred revenue when it receives consideration from a customer before achieving certain criteria that must be met for revenue to be recognized in conformity with GAAP. It can be either current or non-current item. Also called unearned revenue.

UnicoCell Biomed Co's current deferred revenue for the quarter that ended in Jun. 2026 was NT$0.00 Mil.

UnicoCell Biomed Co Current Deferred Revenue Related Terms

UnicoCell Biomed Co Current Deferred Revenue Historical Data

* Premium members only.

The historical data trend for UnicoCell Biomed Co's Current Deferred Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

UnicoCell Biomed Co Current Deferred Revenue Chart

UnicoCell Biomed Co Annual Data
Trend Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Current Deferred Revenue
Get a 7-Day Free Trial Premium Member Only 0.00 0.00 0.00 0.00 0.00

UnicoCell Biomed Co Quarterly Data
Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Current Deferred Revenue Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
TPE:6794
80GF Score
UnicoCell Biomed Co Ltd TPE:6794
Current Deferred Revenue is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
What does a Current Deferred Revenue of NT$0.00 Mil mean?
UnicoCell Biomed Co (TPE:6794) has a Current Deferred Revenue of NT$0.00 Mil as of Jun. 2026. Current Deferred Revenue records the total amount of cash received for unfinished services. View historical data on UnicoCell Biomed Co and its competitors.
Is UnicoCell Biomed Co's Current Deferred Revenue too high?
UnicoCell Biomed Co's current Current Deferred Revenue is NT$0.00 Mil. Overall, UnicoCell Biomed Co has a GF Score™ of 80/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does UnicoCell Biomed Co's Current Deferred Revenue compare to VRTX and REGN?
UnicoCell Biomed Co's Current Deferred Revenue of NT$0.00 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Current Deferred Revenue for a Biotechnology company?
A good Current Deferred Revenue depends on the Biotechnology industry context. However, Current Deferred Revenue should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Current Deferred Revenue mean?
A high Current Deferred Revenue can signal that a stock is expensive relative to its fundamentals. Current Deferred Revenue records the total amount of cash received for unfinished services. View historical data on UnicoCell Biomed Co and its competitors. UnicoCell Biomed Co's current Current Deferred Revenue is NT$0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is UnicoCell Biomed Co stock overvalued right now?
Based on GuruFocus' analysis, UnicoCell Biomed Co (TPE:6794) is currently considered Modestly Overvalued. The stock's GF Value™ is NT$64.97, compared to a current price of NT$71.80 — trading 10.5% above its estimated fair value. The current Current Deferred Revenue is NT$0.00 Mil. UnicoCell Biomed Co's overall GF Score™ is 80/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Current Deferred Revenue calculated?
Current Deferred Revenue is calculated from a company's financial statements. For UnicoCell Biomed Co (TPE:6794), the current Current Deferred Revenue is NT$0.00 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is UnicoCell Biomed Co (TPE:6794) Overvalued in 2026?

Based on GuruFocus' analysis, UnicoCell Biomed Co stock appears to be overvalued. The current stock price of NT$71.80 is trading 10.5% above its estimated GF Value™ of NT$64.97. GuruFocus considers UnicoCell Biomed Co to be Modestly Overvalued.

Key valuation signals for TPE:6794:

  • Current Deferred Revenue: NT$0.00 Mil
  • GF Value™: NT$64.97 vs. price of NT$71.80 (10.5% above fair value)
  • GF Score™: 80/100 with 2 warning signs

No single metric tells the full story. See the TPE:6794 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

UnicoCell Biomed Co Business Description

Address Minquan East Road, 5th Floor, No. 13-20, Section 6, Neihu District, Taipei, TWN, 11494
UnicoCell Biomed Co Ltd is engaged in new drug R&D and human tissue-derived stem cell inspection and testing, extraction, storage, and technology R&D. It focuses on researching and developing stem cells and its derived technology for medical applications, with the goal of advancing human health and improving quality of life. The company's products include Allogeneic Adipose Stem Cell Bank, Autologous Stem Cell Therapy, Conditioned Medium, Mass Production and CDMO, Cryogenic Vial (Class 2 Medical Device), and Testing services. It operates in single segment. Geographically, its operations are spread across Taiwan, Japan and Others with Taiwan generating the majority of the revenue.
80GF Score

Get the complete analysis for TPE:6794

Current Deferred Revenue is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

NT$71.80
Price
NT$64.97
GF Value